Following on from its acquisition of Spanish private hospital group Quironsalud for $6.1bn in 2016, Fresenius SE & Co. KGAA is in talks to acquire US company Akorn Inc.; the generics firm is currently valued at around $3.7bn, which includes an 18% premium following a share price surge when news of the discussions broke. Akorn generated around $1.1bn in sales in 2016.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?